Polypharmacy in Heart Failure: Progress But Also Problem
Am J Med
.
2021 Sep;134(9):1071-1073.
doi: 10.1016/j.amjmed.2021.05.007.
Epub 2021 May 26.
Authors
Parag Goyal
1
,
Sabrina Mangal
2
,
Ashok Krishnaswami
3
,
Michael W Rich
4
Affiliations
1
Department of General Internal Medicine, Division of Cardiology, Weill Cornell Medicine, New York, NY. Electronic address: pag9051@med.cornell.edu.
2
Department of Population Health Sciences, Weill Cornell Medicine, New York, NY.
3
Division of Cardiology, Kaiser Permanente San Jose Medical Center, San Jose, Calif.
4
Cardiovascular Division, Washington University School of Medicine, St. Louis, Mo.
PMID:
34051153
PMCID:
PMC10326723
DOI:
10.1016/j.amjmed.2021.05.007
No abstract available
Publication types
Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Heart Failure* / drug therapy
Humans
Polypharmacy*
Grants and funding
K76 AG064428/AG/NIA NIH HHS/United States
L30 AG060521/AG/NIA NIH HHS/United States